Polypeptide for inhibiting joint inflammations in mice and application thereof

A technology for arthritis and small molecule peptides, applied in the direction of peptides, peptide sources, anti-inflammatory agents, etc.

Inactive Publication Date: 2019-01-22
AFFILIATED HOSPITAL OF JIANGSU UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the schistosome polypeptide that inhibits collagen-induced arthritis in mice

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide for inhibiting joint inflammations in mice and application thereof
  • Polypeptide for inhibiting joint inflammations in mice and application thereof
  • Polypeptide for inhibiting joint inflammations in mice and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: Construction of collagen-induced arthritis (collagen induced arthritis, CIA) mouse model:

[0019] 1) 200 μg of bovine type II collagen (CII, purchased from BD Bioscience) was mixed with complete Freund's adjuvant (CFA) in equal amounts to make an emulsifier, and DBA / 1 mice were subcutaneously immunized at the base of the tail on day 0 and 21, and co-immunized 2 times. CFA was prepared by adding 4 mg / ml Mycobacterium Tuberculosis H37RA (Difco) to Incomplete Freund's Adjuvant (IFA, purchased from Sigma). And through the clinical scoring and histological identification of joint inflammation, it was verified that the construction of CIA mice was successful.

[0020] 2) After CII immunization on the 21st day, two people double-blindly observed the condition of each paw of the mouse every other day: 0=no change; 1=slight swelling and / or erythema; 2=moderate swelling and erythema; 3= Marked swelling and erythema; maximum clinical score of 12 in 4 paws per mouse. ...

Embodiment 2

[0021] Example 2: SJMHE1 treatment of CIA mice;

[0022] 1) Mice were divided into 7 groups: CIA, PBS, 10 μg SJMHE1, 10 μg OVA 323-339 (control peptide group), and group (normal control group); the PBS, SJMHE1, OVA 323-339 Mix it with IFA in equal amount to make an emulsifier, inject mice subcutaneously into the tail spine, the injection dose is 100 μl / only; treat on the 7th day (d7) of bovine type II collagen (CII) immunization, and inject subcutaneously every 14 days , a total of 3 injections; mice in each treatment group were clinically scored and histologically identified for joint inflammation, and serum anti-CII IgG, IgG1, and IgG2a antibodies were detected to verify the therapeutic effect of SJMHE1.

[0023] 2) Collect mouse serum, and detect CII-specific IgG, IgG1, IgG2a in mouse serum by ELISA. Namely: ELISA plates were coated with 5 μg / ml CII, and refrigerated overnight at 4°C. Each reaction plate was washed 3 times with PBS-T and then blocked with 0.3% BSA at 3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a polypeptide for inhibiting joint inflammations in mice and application thereof. The micro-molecule polypeptide SJMHE1 originated from the egg and imago antigens of Schistosoma japonicum consists of 24 amino acids, is a T cell epitope shared by human and mouse HSP60 molecules, and can prevent and treat collagen-induced arthritis in mice. The polypeptide of the invention has the beneficial benefits that the polypeptide can be used for treating rheumatoid arthritis and has potential new drug development value.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a polypeptide for inhibiting joint inflammation in mice and application thereof. Background technique [0002] Rheumatoid arthritis (rheumatoid arthritis, RA) affects about 1% of the world's population, and the incidence rate in my country is about 0.3-0.5%. The disability rate of RA is very high, and the disability rate of untreated RA patients is 2-3 years As high as 70%, resulting in the loss of the ability to work as many as ten million people, has become a serious threat to human health disease [1] . At present, the clinical treatment of RA is still dominated by non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs, and glucocorticoids and cytotoxic immunosuppressants are also commonly used. , It is difficult for patients to take it for a long time. Therefore, there is an urgent need to seek new specific targets or new intervention methods to treat ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/435A61K38/17A61P29/00A61P19/02
CPCA61K38/00C07K14/43559Y02A50/30
Inventor 汪雪峰毛朝明陈德玉舒扬冯玎琦
Owner AFFILIATED HOSPITAL OF JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap